These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 3528243)

  • 1. Topical clobetasol-17-propionate: review of its clinical efficacy and safety.
    Olsen EA; Cornell RC
    J Am Acad Dermatol; 1986 Aug; 15(2 Pt 1):246-55. PubMed ID: 3528243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines for using superpotent topical steroids.
    Prawer SE; Katz HI
    Am Fam Physician; 1990 May; 41(5):1531-8. PubMed ID: 2333829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids.
    Walsh P; Aeling JL; Huff L; Weston WL
    J Am Acad Dermatol; 1993 Sep; 29(3):501-3. PubMed ID: 8349876
    [No Abstract]   [Full Text] [Related]  

  • 4. Intermittent topical treatment of psoriasis with clobetasol propionate ("Dermovate").
    Svartholm H; Larsson L; Frederiksen B
    Curr Med Res Opin; 1982; 8(3):154-7. PubMed ID: 6751703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Halogenation and topical corticosteroids: a comparison between the 17-butyrate esters of hydrocortisone and clobetasone in ointment bases.
    Allenby CF; Sparkes CG
    Br J Dermatol; 1981 Feb; 104(2):179-83. PubMed ID: 7011356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis.
    Andres P; Poncet M; Farzaneh S; Soto P
    J Drugs Dermatol; 2006 Apr; 5(4):328-32. PubMed ID: 16673799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Double-blind-study on treatment with clobetasol-17-propionate and other topical corticoids (author's transl)].
    Beck M; Berger C; Filipp N; Hundertmark U; Loewel R
    Z Hautkr; 1981 Aug; 56(16):1066-70. PubMed ID: 7027655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clobetasol propionate versus fluocinonide creams in psoriasis and eczema.
    Jegasothy B; Jacobson C; Levine N; Millikan L; Olsen E; Pinnell S; Cole G; Weinstein G; Porter M
    Int J Dermatol; 1985 Sep; 24(7):461-5. PubMed ID: 3902682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of value and risks of external treatment with clobetasol-17-propionate (Dermovate)].
    van der Harst LC; Smeenk G; Burger PM; van der Rhee HJ; Polano MK
    Ned Tijdschr Geneeskd; 1978 Feb; 122(7):219-23. PubMed ID: 345134
    [No Abstract]   [Full Text] [Related]  

  • 10. Clobetasol propionate emollient 0.05 percent: hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasis.
    Jorizzo JL; Magee K; Stewart DM; Lebwohl MG; Rajagopalan R; Brown JJ
    Cutis; 1997 Jul; 60(1):55-60. PubMed ID: 9252738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenal suppression following low-dose topical clobetasol propionate.
    Ohman EM; Rogers S; Meenan FO; McKenna TJ
    J R Soc Med; 1987 Jul; 80(7):422-4. PubMed ID: 3656312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superpotent topical steroid treatment of psoriasis vulgaris--clinical efficacy and adrenal function.
    Katz HI; Hien NT; Prawer SE; Mastbaum LI; Mooney JJ; Samson CR
    J Am Acad Dermatol; 1987 Apr; 16(4):804-11. PubMed ID: 3553247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with 0.05% clobetasol propionate creams.
    Richards RN
    J Am Acad Dermatol; 1985 May; 12(5 Pt 1):891-3. PubMed ID: 4008693
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy, safety, and cost-effectiveness of all-trans retinoic acid/Clobetasol Propionate Compound Ointment in the treatment of mild to moderate psoriasis vulgaris: A randomized, single-blind, multicenter clinical trial.
    Xia L; Li R; Wang Y; Lin Z; Zheng J; Li X; Lu Q; Zhang J; Jin H; Fu L; Zhang X; Liu Y; Yang S; Xiao F; Gao XH
    Dermatol Ther; 2018 Sep; 31(5):e12632. PubMed ID: 30253049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrophic skin striae following the use of clobetasol propionate ointment.
    Hardie RA; Waring AJ; Barnetson RS
    Practitioner; 1977 Sep; 219(1311):376-8. PubMed ID: 928283
    [No Abstract]   [Full Text] [Related]  

  • 16. The use and abuse of 0.05 per cent clobetasol propionate in dermatology.
    Harris DW; Hunter JA
    Dermatol Clin; 1988 Oct; 6(4):643-7. PubMed ID: 3229014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoriasis treatment: faster clearance when UVB-dithranol is combined with topical clobetasol propionate.
    Lidbrink P; Johannesson A; Hammar H
    Dermatologica; 1986; 172(3):164-8. PubMed ID: 3699218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing chronic skin conditions with two differing topical corticosteroids.
    Woodbridge PA; Sparkes CG
    Dermatologica; 1979; 158(4):299-306. PubMed ID: 428616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generalized pustular psoriasis associated with withdrawal of topical clobetasol-17-propionate.
    Telfer NR; Dawber RP
    J Am Acad Dermatol; 1987 Jul; 17(1):144-5. PubMed ID: 3611449
    [No Abstract]   [Full Text] [Related]  

  • 20. Clobetasol-17 propionate lotion under hydrocolloid dressing (Duoderm ET) once weekly versus unoccluded clobetasol-17-propionate ointment twice daily in psoriasis: an immunohistochemical study on remission and relapse.
    van der Vleuten CJ; van Vlijmen-Willems IM; de Jong EM; van de Kerkhof PC
    Arch Dermatol Res; 1999; 291(7-8):390-5. PubMed ID: 10482007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.